An Examination of the Complex Pharmacological Properties of the Non-Selective Opioid Modulator Buprenorphine.  Pande LJ, Arnet RE, Piper BJ.  Pharmaceuticals (Basel). 2023 Oct 2;16(10):1397. doi: 10.3390/ph16101397. PMID: 37895868; PMCID...

Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey: Findings from a longitudinal qualitative study.  Parkin S, Neale J, Strang J.  Int J Drug Policy. 2023 Oct 19;122:10...

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder.  Flam-Ross JM, Marsh E, Weitz M, Savinkina A, Schackman BR, Wang J, Madushani RWMA, Morgan JR, Barocas JA, Walley AY, Chrysanthopoulou SA, Linas BP, A...

The experience of buprenorphine implant in patients with opioid use disorder: a series of narrative interviews.  Scurti P, Nunzi M, Leonardi C, Pierlorenzi C, Marenzi R, Lamartora V.  Front Psychiatry. 2023 Aug 31;14:1205285. doi: 10.338...

Challenges of Estimating the Value of Buprenorphine Injectables.  Nelson LS, Perrone J.  JAMA Netw Open. 2023 Sep 5;6(9):e2329677. doi: 10.1001/jamanetworkopen.2023.29677. PMID: 37703021. https://jamanetwork.com/journals/jamanetworkopen/...

Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use.  Pytell JD, Fojo AT, Keruly JC, Snow LN, Falade-Nwulia O, Moore...